{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:52:37Z","timestamp":1780080757222,"version":"3.54.0"},"reference-count":8,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T00:00:00Z","timestamp":1409270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Graceway Pharmaceuticals, LLC"},{"name":"Meda Pharma GmbH & Co. KG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,9]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>In patients with actinic keratosis (AK<\/jats:styled-content>), subclinical and clinical lesions coexist across large areas of sun\u2010exposed skin. The long\u2010term efficacy of AK<\/jats:styled-content> treatments depends on their ability to eradicate both types of lesions across the entire field.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the long\u2010term efficacy of imiquimod 3.75% using the reduction in lesions from Lmax (maximum lesion count during treatment), which assesses the ability to clear subclinical and clinical lesions.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients with 5\u201320 AK<\/jats:styled-content> lesions on the full face or balding scalp from two 14\u2010week, randomized, vehicle\u2010controlled, double\u2010blind studies of imiquimod 3.75% (daily for two 2\u2010week treatment cycles separated by a 2\u2010week treatment\u2010free period) were eligible to enter a 12\u2010month follow\u2010up study if they had no AK<\/jats:styled-content> lesions at Week 14. Lesion reduction from Lmax was calculated at 6 and 12\u00a0months during follow\u2010up.<\/jats:p><\/jats:sec>Results<\/jats:title>The 42 patients in this long\u2010term study had a median of nine baseline lesions and a median Lmax of 22 lesions. At 6 and 12\u00a0months of follow\u2010up, the median absolute reduction in AK<\/jats:styled-content> lesions from Lmax with imiquimod 3.75% was 21 and 19, respectively. The median percentage reduction in lesions from Lmax to 6 and 12\u00a0months was 100% and 97.2%, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The ability of imiquimod 3.75% to eliminate clinical and subclinical lesions across an entire sun\u2010exposed field translates into sustained long\u2010term efficacy. Imiquimod 3.75% may therefore represent a first\u2010choice treatment for patients with AK<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12697","type":"journal-article","created":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T13:47:58Z","timestamp":1409320078000},"page":"1840-1842","source":"Crossref","is-referenced-by-count":8,"title":["Long\u2010term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field\u2010directed treatment for actinic keratosis"],"prefix":"10.1111","volume":"29","author":[{"given":"G.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Dermatology Monklands Hospital Airdrie Lanarkshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Stockfleth","sequence":"additional","affiliation":[{"name":"Department of Dermatology Charit\u00e9 \u2013 University Medical Centre Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peris","sequence":"additional","affiliation":[{"name":"Department of Dermatology Catholic University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aractingi","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Allergologie H\u00f4pital Cochin Paris France"},{"name":"Universit\u00e9 Paris 5 Descartes Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alomar","sequence":"additional","affiliation":[{"name":"Department of Dermatology Institut Universitari Quiron Dexeus Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dakovic","sequence":"additional","affiliation":[{"name":"Meda Pharma GmbH & Co. KG Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dirschka","sequence":"additional","affiliation":[{"name":"Dermatological Practice Centre Wuppertal Germany"},{"name":"Faculty of Health University Witten\u2010Herdecke Witten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,29]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: a comprehensive strategy","volume":"11","author":"Stockfleth E","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"e_1_2_6_3_1","first-page":"3","article-title":"Actinic keratosis and field cancerisation","volume":"21","author":"Stockfleth E","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_4_1","first-page":"227","article-title":"Zyclara (imiquimod) cream, 3.75%","volume":"8","author":"Gupta AK","year":"2010","journal-title":"Skinmed"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ejd.2014.2265","article-title":"Reduction in lesions from Lmax: a new concept for assessing efficacy of field\u2010directed therapy for actinic keratosis. Results with imiquimod 3.75%","volume":"24","author":"Stockfleth E","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_7_1","first-page":"165","article-title":"Complete clearance is sustained for at least 12\u00a0months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream","volume":"10","author":"Hanke CW","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_8_1","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus","volume":"18","author":"Stockfleth E","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_9_1","first-page":"1101","article-title":"A randomized, double\u2010blinded, placebo\u2010controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses","volume":"9","author":"Jorizzo JL","year":"2010","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12697","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:14:02Z","timestamp":1695492842000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,29]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/jdv.12697"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12697","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,29]]}}}